Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer

Press/Media: Press / Media

Period2022 Sep 7 → 2022 Sep 9

Media coverage

23

Media coverage